• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Vascular endothelial growth factor expression is increased in renal cell carcinoma.

作者信息

Nicol D, Hii S I, Walsh M, Teh B, Thompson L, Kennett C, Gotley D

机构信息

Department of Surgery, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.

出版信息

J Urol. 1997 Apr;157(4):1482-6.

PMID:9120987
Abstract

PURPOSE

To compare the expression of VEGF in renal cell carcinoma (RCC) and normal kidney.

MATERIALS AND METHODS

RT-PCR and Western blot analysis were performed on tumour and normal adjacent kidney collected from 31 patients (29 RCC and 2 oncocytomas) as well as proliferating vascular endothelial cells (VEC) in culture.

RESULTS

Expression of 3 VEGF isoforms was detected in normal renal parenchyma and all ROC by RT-PCR, but was not apparent in proliferating VEC. In 27 RCC, Western blot analysis demonstrated 3-37 fold increases in VEGF expression when compared to normal parenchyma. Immunohistochemistry demonstrated VEGF staining of both tumour cells and adjacent vascular endothelium. Normal kidney showed no staining for VEGF. In the 2 remaining RCC and both oncocytomas VEGF was not increased.

CONCLUSIONS

VEGF expression is increased in RCC and may have a paracrine effect in these tumours in stimulating angiogenesis.

摘要

相似文献

1
Vascular endothelial growth factor expression is increased in renal cell carcinoma.
J Urol. 1997 Apr;157(4):1482-6.
2
Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.肾细胞癌中缺氧诱导因子2α的上调与Tsc-2肿瘤抑制基因缺失相关。
Cancer Res. 2003 May 15;63(10):2675-80.
3
Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma.通过竞争性定量逆转录聚合酶链反应对肾细胞癌中VEGF121和VEGF165进行定量分析。
Anticancer Res. 1999 Mar-Apr;19(2C):1563-5.
4
A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.一种鼠源血管内皮生长因子抗体可抑制人Caki-I肾腺癌的体内生长。
Anticancer Res. 2003 Mar-Apr;23(2B):1625-30.
5
Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.透明细胞肾细胞癌和乳头状肾细胞癌之间不同的血管内皮生长因子(VEGF)、VEGF受体1和-2 mRNA表达谱。
BJU Int. 2006 Sep;98(3):661-7. doi: 10.1111/j.1464-410X.2006.06387.x.
6
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.血管内皮生长因子抑制性剪接变体VEGF165b在肾细胞癌中表达下调。
Cancer Res. 2002 Jul 15;62(14):4123-31.
7
[Vascular endothelial growth factor gene expression in nasopharyngeal carcinoma cell line induced by hypoxia in vitro].[体外缺氧诱导鼻咽癌细胞系中血管内皮生长因子基因的表达]
Ai Zheng. 2003 Feb;22(2):160-3.
8
VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.血管内皮生长因子(VEGF)和血管内皮生长因子受体-1(VEGFR-1)在肾细胞癌的上皮细胞和基质细胞中共同表达。
Cancer. 2008 Jan 15;112(2):433-42. doi: 10.1002/cncr.23186.
9
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.血管内皮生长因子(VEGF)在头颈部鳞状细胞癌中的预后价值
Br J Cancer. 2000 Sep;83(6):775-81. doi: 10.1054/bjoc.2000.1357.
10
Shear stress regulates occludin and VEGF expression in porcine arterial endothelial cells.剪切应力调节猪动脉内皮细胞中闭合蛋白和血管内皮生长因子的表达。
J Surg Res. 2002 Jan;102(1):13-21. doi: 10.1006/jsre.2001.6295.

引用本文的文献

1
The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features.透明细胞肾细胞癌中血管生成拟态的分类揭示了其与临床及免疫特征的内在联系。
Front Pharmacol. 2023 Dec 20;14:1333507. doi: 10.3389/fphar.2023.1333507. eCollection 2023.
2
Differential expression of and its downstream target in the main subtypes of renal cell carcinoma and their impact on patient survival.[某物质]及其下游靶点在肾细胞癌主要亚型中的差异表达及其对患者生存的影响。 (注:原文中“Differential expression of and its downstream target ”部分“of”后面缺少具体物质,这里用“[某物质]”暂代)
Front Oncol. 2023 Nov 20;13:1287239. doi: 10.3389/fonc.2023.1287239. eCollection 2023.
3
Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib.
一线舒尼替尼治疗转移性透明细胞肾细胞癌患者中 VEGF、CD31 和 Ang-1 的预后和预测意义。
Biomol Biomed. 2023 Feb 1;23(1):161-169. doi: 10.17305/bjbms.2022.7675.
4
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.转谷氨酰胺酶 2 介导的 p53 耗竭通过增加 HIF-1α-p300 结合促进肾细胞癌血管生成。
Int J Mol Sci. 2020 Jul 17;21(14):5042. doi: 10.3390/ijms21145042.
5
Renal cell tumors convert natural killer cells to a proangiogenic phenotype.肾细胞肿瘤将自然杀伤细胞转变为促血管生成表型。
Oncotarget. 2020 Jun 30;11(26):2571-2585. doi: 10.18632/oncotarget.27654.
6
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.转移性透明细胞肾细胞癌抗血管生成治疗的预后及疗效生物标志物
Front Oncol. 2019 Dec 11;9:1400. doi: 10.3389/fonc.2019.01400. eCollection 2019.
7
Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.改善高危肾细胞癌辅助治疗的患者选择。
Ann Transl Med. 2019 Jul;7(Suppl 3):S104. doi: 10.21037/atm.2019.04.75.
8
Synchronous retroperitoneal Castleman's disease with clear cell renal cell carcinoma.伴有透明细胞肾细胞癌的同步性腹膜后Castleman病
BMJ Case Rep. 2019 Sep 16;12(9):e230919. doi: 10.1136/bcr-2019-230919.
9
Decreased capillary density in renal cell carcinoma: Evidence from a case report with micro-computerized tomography.肾细胞癌中毛细血管密度降低:来自一例微计算机断层扫描病例报告的证据。
Medicine (Baltimore). 2019 Sep;98(36):e16910. doi: 10.1097/MD.0000000000016910.
10
High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.基于芯片上心脏模型的高通量心脏功能评估及其在药物筛选中的应用
Stem Cell Rev Rep. 2017 Jun;13(3):335-346. doi: 10.1007/s12015-017-9736-2.